ONCR-177 is a genetically modified oncolytic HSV-1 that retains one copy of ICP34.5 to increase resistance to IFN signaling44 and uses miRNA-mediated suppression of key viral genes to provide tumor-specific replication and safety. This evidence concerns the gene IFNA1 and neoplasm.